deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT02143388

Concurrent Cisplatin Chemoradiation With or Without Capecitabine as Adjuvant Chemotherapy in Local Advanced High Risk Nasopharyngeal Carcinoma: Randomized Control Clinical Trial

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Conditions Local Advanced High Risk Nasopharyngeal Carcinoma
Interventions IMRT combine with cisplatin concurrent chemotherapy IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy
Updated 13 times since 2017 Last updated: Aug 30, 2022 Started: Mar 31, 2014 Primary completion: Jul 27, 2018 Completion: Aug 5, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02143388, this PHASE3 trial focuses on Local Advanced High Risk Nasopharyngeal Carcinoma and remains completed. Sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, it has been updated 13 times since 2014, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Mar 2018 · 14 months · monthly snapshot~Mar 2018 – ~May 2018 · 2 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Feb 2019 · 8 months · monthly snapshot~Feb 2019 – ~May 2019 · 3 months · monthly snapshot~May 2019 – ~Jan 2021 · 20 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Jan 2022 · 4 months · monthly snapshot~Jan 2022 – ~Apr 2022 · 3 months · monthly snapshot~Apr 2022 – ~Sep 2022 · 5 months · monthly snapshot~Sep 2022 – ~Jul 2024 · 22 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

13 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Sep 2022 — Jul 2024 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  4. Apr 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE3

    Phase: PHASE2_PHASE3 → PHASE3

  5. Jan 2022 — Apr 2022 [monthly]

    Active Not Recruiting PHASE2_PHASE3

    Status: Completed → Active Not Recruiting

▶ Show 8 earlier versions

  1. Sep 2021 — Jan 2022 [monthly]

    Completed PHASE2_PHASE3

    Status: Active Not Recruiting → Completed

  2. Jan 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE2_PHASE3

  3. May 2019 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2_PHASE3

  4. Feb 2019 — May 2019 [monthly]

    Active Not Recruiting PHASE2_PHASE3

    Status: Recruiting → Active Not Recruiting

  5. Jun 2018 — Feb 2019 [monthly]

    Recruiting PHASE2_PHASE3

  6. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE2_PHASE3

  7. Mar 2018 — May 2018 [monthly]

    Recruiting PHASE2_PHASE3

    Phase: PHASE2 → PHASE2_PHASE3

  8. Jan 2017 — Mar 2018 [monthly]

    Recruiting PHASE2

    First recorded

Mar 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences
  • Jiangxi Provincial Cancer Hospital
  • National Cancer Centre, Singapore
  • Zhao Chong
Data source: Sun Yat-sen University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations